Advertisement

U.S. markets closed

S&P Futures
4,134.50
-13.25(-0.32%)
Dow Futures
33,888.00
-74.00(-0.22%)
Nasdaq Futures
12,574.00
-50.00(-0.40%)
Russell 2000 Futures
1,985.70
-7.80(-0.39%)
Crude Oil
73.58
+0.19(+0.26%)
Gold
1,886.60
+10.00(+0.53%)

Advertisement

bluebird bio, Inc. (BLUE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Visitors trend2W10W9M

6.65

+0.02

(+0.30%)

At close: 04:00PM EST

6.67

+0.02

(+0.30%)

After hours:

07:43PM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

MACD

View all chart patterns

Performance Outlook

Previous Close	6.63
Open	6.40
Bid	6.55 x 1300
Ask	6.68 x 900
Day's Range	6.37 - 6.82
52 Week Range	2.87 - 8.58
Volume	3,010,142
Avg. Volume	3,786,280

Market Cap	684.438M
Beta (5Y Monthly)	0.98
PE Ratio (TTM)	N/A
EPS (TTM)	-10.43
Earnings Date	Mar 02, 2023 - Mar 06, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	7.33

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BLUE

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

bluebird bio, Inc.
Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Rating
Fair Value
Economic Moat
3 days agoMorningstar

All

American City Business Journals
Here's why 2seventy bio's chief executive thinks 2023 will be a 'special year'
The chief executive of bluebird bio's oncology-focused spinout believes that this year, it will take off as a company in its own right.
Simply Wall St.
bluebird bio, Inc. (NASDAQ:BLUE) is favoured by institutional owners who hold 58% of the company
Every investor in bluebird bio, Inc. ( NASDAQ:BLUE ) should be aware of the most powerful shareholder groups. And the...
Zacks
Zacks.com featured highlights include bluebird bio, Pros Holdings and Norwegian Cruise Line
bluebird bio, Pros Holdings and Norwegian Cruise Line are part of the Zacks Screen of the Week article.

Advertisement

S&P Futures4,134.50-13.25(-0.32%)

Dow Futures33,888.00-74.00(-0.22%)

Nasdaq Futures12,574.00-50.00(-0.40%)

Russell 2000 Futures1,985.70-7.80(-0.39%)

Crude Oil73.58+0.19(+0.26%)

Gold1,886.60+10.00(+0.53%)

bluebird bio, Inc. (BLUE)

Chart Events

Performance Outlook

Fair Value

Related Research

Here's why 2seventy bio's chief executive thinks 2023 will be a 'special year'

bluebird bio, Inc. (NASDAQ:BLUE) is favoured by institutional owners who hold 58% of the company

Zacks.com featured highlights include bluebird bio, Pros Holdings and Norwegian Cruise Line

S&P Futures
4,134.50
-13.25(-0.32%)

Dow Futures
33,888.00
-74.00(-0.22%)

Nasdaq Futures
12,574.00
-50.00(-0.40%)

Russell 2000 Futures
1,985.70
-7.80(-0.39%)

Crude Oil
73.58
+0.19(+0.26%)

Gold
1,886.60
+10.00(+0.53%)